Summit Expands Ivonescimab Into Bladder Cancer With Phase 3 HARMONi-GU1 Trial

Summit Therapeutics (SMMT) announced the launch of HARMONi-GU1 on August 5, a global Phase 2/3 registrational trial evaluating ivonescimab in combination with enfortumab vedotin (Padcev) against pembrolizumab plus Padcev in first-line locally advanced or metastatic urothelial carcinoma. The trial expects to enroll approximately 800 patients and represents the first ivonescimab study in a genitourinary cancer.

Ivonescimab is a PD-1/VEGF bispecific antibody: a single molecule that simultaneously blocks the PD-1 immune checkpoint and traps VEGF, the protein that drives blood vessel growth in tumors. Summit believes this dual mechanism fits bladder cancer because both angiogenesis and immune evasion are features of urothelial carcinoma biology. The trial design is aggressive: it goes head-to-head against pembrolizumab plus Padcev, the current standard of care that earned full FDA approval for muscle-invasive bladder cancer. Summit is not testing ivonescimab against placebo; it is trying to beat the best available regimen.

Bladder cancer is a significant market. Roughly 84,500 new cases are expected in the US in 2026, with a global burden exceeding 635,000 diagnoses annually. First-line metastatic disease carries poor long-term outcomes: median overall survival remains under two years even with the best available therapies. The pembrolizumab-Padcev combination improved overall survival by 6.8 months in the EV-302 trial that established the standard, and ivonescimab’s VEGF component could add a durability benefit on top of checkpoint inhibition. Summit is betting that hitting both PD-1 and VEGF in one molecule outperforms giving a checkpoint inhibitor and an ADC separately.

HARMONi-GU1 brings ivonescimab’s total to 16 active Phase 3 trials spanning non-small cell lung cancer, colorectal, pancreatic, head and neck, kidney, and now bladder cancers. The breadth reflects Summit’s thesis that ivonescimab is a pipeline-in-a-product rather than a one-indication drug: one bispecific antibody targeting multiple solid tumors through a single mechanism.

The near-term event remains the November 14 PDUFA date for ivonescimab in NSCLC. With the stock at $13.54 and a roughly $11 billion market cap, most of that valuation hangs on the NSCLC decision. HARMONi-GU1 will not produce registrational data before that catalyst. It signals Summit’s confidence that ivonescimab can compete broadly, and its willingness to spend heavily on trials while carrying zero commercial revenue.

Summit ended Q1 2026 with roughly $2.7 billion in cash, enough to fund operations through at least 2027. But 16 Phase 3 trials in parallel consume capital at a rate few pre-revenue biotechs attempt. If the November PDUFA disappoints, the bladder cancer trial and most of the pipeline may not matter.